Premium
Electrophysiological evidence for trigeminal neuron sensitization in patients with migraine.
Author(s) -
Sandrini G,
Proietti Cecchini A,
Milanov I,
Tassorelli C,
Buzzi MG,
Nappi G
Publication year - 2003
Publication title -
headache: the journal of head and face pain
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.14
H-Index - 119
eISSN - 1526-4610
pISSN - 0017-8748
DOI - 10.1046/j.1526-4610.2003.03062_11.x
Subject(s) - migraine , aura , corneal reflex , medicine , trigeminal nerve , anesthesia , reflex , cortical spreading depression , electrophysiology , central sensitization , neuroscience , nociception , psychology , receptor
Neurosci Lett . 2002 Jan 14;317(3):135‐138 The electrically elicited corneal reflex is a useful tool for exploring the trigeminal system in humans and it may provide additional evidence pointing to a dysfunction of this system in migrainous patients. Tactile perception, corneal reflex and pain thresholds were studied in 48 migraine without aura patients during pain‐free periods and compared with those observed in 24 controls. Twenty‐eight of the patients had strictly unilateral headache, while the other 20 had bilateral or side‐shifting pain during attacks. Both migraine subgroups (bilateral and unilateral) showed significantly lower thresholds compared with controls. The lowest values were observed on the symptomatic side of unilateral migraine patients. These findings suggest that sensorimotor mechanisms and/or pain control systems at the trigeminal level are impaired in migraine. The bilateral location of these abnormalities seems to point to a centrally located dysfunction. Comment: This is an important paper which describes a noninvasive method of studying sensorimotor/pain control mechanism in humans. This approach may help in the development of potential prophylactic agents, to establish likely clinically effective doses and duration of treatments in small‐scale phase II trials, before exposing larger numbers of subjects to potentially ineffective doses in phase III trials. DSM